Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Keros Therapeutics ( (KROS) ).
On October 15, 2025, Keros Therapeutics announced a $375 million capital return program, including repurchasing shares from ADAR1 Capital Management and Pontifax Venture Capital for approximately $181 million. This move, alongside a planned tender offer for additional shares, reflects Keros’ confidence in its financial position and clinical strategy, particularly for its KER-065 program. The resignations of board members Tomer Kariv and Ran Nussbaum were also announced, with Jean-Jacques Bienaimé appointed as the new Chair of the Nominating and Corporate Governance Committee. The company plans to distribute part of its Takeda licensing revenue to shareholders, aiming to enhance long-term stockholder value.
The most recent analyst rating on (KROS) stock is a Hold with a $16.00 price target. To see the full list of analyst forecasts on Keros Therapeutics stock, see the KROS Stock Forecast page.
Spark’s Take on KROS Stock
According to Spark, TipRanks’ AI Analyst, KROS is a Neutral.
Keros Therapeutics’ overall score is driven by its strong financial performance, particularly its profitability and balance sheet strength. However, technical indicators suggest mixed signals, and the high P/E ratio indicates potential overvaluation. The absence of earnings call data and corporate events limits further insights.
To see Spark’s full report on KROS stock, click here.
More about Keros Therapeutics
Keros Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat disorders linked to dysfunctional signaling of the TGF-ß family of proteins. The company is a leader in understanding the role of these proteins in regulating tissue growth, repair, and maintenance, and is developing therapeutics with potential disease-modifying benefits. Keros’ lead product candidate, KER-065, targets neuromuscular diseases, including Duchenne muscular dystrophy, while its advanced candidate, elritercept, addresses cytopenias in myelodysplastic syndrome and myelofibrosis.
Average Trading Volume: 437,780
Technical Sentiment Signal: Hold
Current Market Cap: $645.4M
See more insights into KROS stock on TipRanks’ Stock Analysis page.